InterMune Inc. (ITMN)

[someconcerns]

My WAG is that there will be a buyout at somewhere between $60 and $70. Of course, after the pop when some study results were released it did dip below $25 before more buy recommendations were issued. The larger firms which could do the buyout are clearly more interested in the US market, with higher drug prices, than in Europe, where I think the traction for Esbriet is real.

No idea how soon the FDA will act and no idea which estimates of the patient population are more accurate. My guess is they are using differing definitions with a lot of assumptions.

What I do think is that the potential gain for a buyout - percentage-wise - is less than the pop we had on study results.